Form 4: Tempest Therapeutics Chief Medical Officer Acquires 270,000 Stock Options

Tempest Therapeutics' Chief Medical Officer, Samuel Whiting, was granted 270,000 stock options on January 2, 2025, according to a recent SEC filing.

Summary

• Samuel Whiting, the Chief Medical Officer of Tempest Therapeutics, acquired 270,000 stock options on January 2, 2025.
• The options have an exercise price of $0.86 per share.
• These options vest in 48 equal monthly installments starting from January 2, 2025, contingent on Mr. Whiting's continued employment.
• The options expire on January 1, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management interests with shareholders. There is no indication of any negative or unexpected events.

Positives

• The grant of stock options to the Chief Medical Officer aligns his interests with the company's long-term success.
• The vesting schedule encourages continued service from the executive.

Industry Context

This is a standard practice for incentivizing key executives in publicly traded companies, particularly in the biotech sector.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for executives in publicly traded companies, especially in the biotech industry.
• Vesting schedules, such as the 48-month monthly vesting in this case, are typical to ensure long-term commitment from the executive.
• The exercise price of $0.86 is a common practice, often set at or near the market price at the time of the grant.

Stakeholder Impact

• The stock option grant could potentially benefit shareholders if the company performs well and the options become valuable.
• The grant incentivizes the Chief Medical Officer to contribute to the company's success.

Key Dates

Keywords

stock options, insider trading, executive compensation, SEC Form 4, Tempest Therapeutics, TPST, Samuel Whiting, Chief Medical Officer